the specific mechanisms are not fully clarified, the growth-promoting effect of ZnO likely benefits from the improvement of gut health, including reduced secretory responses, reduced inflammation, improved intestinal histomorphology and mucin composition, increased mucosal insulin-like growth factor-I expression, enhanced tight junction integrity and the adjustment of gut microbiota (Carlson, Poulsen, & Sehested, 2004; Hu, Song, Li, Luan, & Zhu, 2013; Li et al., 2006; Liu et al., 2014; Mavromichalis, Peter, Parr, Ganessunker, & Baker, 2000) . However, the long-term use of ZnO at pharmacological dosage can produce toxic symptoms characterized by depressed feed intake and efficiency of gain (Brink, Becker, Terrill, & Jensen, 1959) . Further, feeding of high ZnO dosages may stimulate the occurrence of resistance to Zn in the pig gut bacteria and may play a role in the co-selection of antibiotic resistance (Cavaco, Hasman, & Aarestrup, 2011; EFSA, 2014) . High dietary ZnO leads to excessive faecal Zn excretion (Buff, Bollinger, Ellersieck, Brommelsiek, & Veum, 2005; Case & Carlson, 2002) , and hence the accumulation of Zn in soils after intensive pig farming is concerned as a serious environmental issue (Romeo, Vacchina, Legros, & Doelsch, 2014) . In 2017, in the EU, the Commission voted in favour of phasing out pharmacological ZnO, ultimately by 2022 (Commission Implementing Decision of 26.6.2017 26.6. , C(2017 . Therefore, new Zn formulations applied at lower dosages that might provide equal efficacy (Cho, Upadhaya, & Kim, 2015; Han, Ma, Lv, Wu, & Qian, 2014) , or other approaches to reduce post-weaning scouring (Michiels, VanNoten, & Degroote, 2017) , deserves full attention. HiZox ® (Animine, Sillingy, France) is ZnO and is prepared by a patented manufacturing technology providing unique physico-chemical features, such as high purity standards, high specific surface area from elevated porosity and unique particle size and shape, according to supplier information. Cardoso, Chevalier, and Romeo (2017) employed low-angle laser light scattering, electron microscopy and BET nitrogen adsorption isotherms to differentiate feed-grade zinc oxide sources in terms of particle size, morphology and specific area. HiZox ® represented different characteristics than conventional ZnO sources. It showed aggregates having a sponge internal structure, whereas other sources were dense materials. Also, it presented large agglomerates and small aggregates, while other samples did not differ from aggregates and agglomerates. The potentiated ZnO showed a porous high specific area, whereas others had very low specific area and were not porous. For example, the potentiated ZnO had a specific surface area of 42 m 2 /g versus 0.5-2.4 m 2 /g for other ZnO sources. This potentiated ZnO source contains minimum 75% Zn. Ex vivo, in chyme from donor piglets that was supplemented with ZnO sources, it was shown that this ZnO source showed higher solubility and enhanced bacterial growth reduction more drastic and more rapid as compared to analytical
ZnO at the same concentration (Vahjen, Zentek, & Durosoy, 2012 2012). Cho et al. (2015) demonstrated that this alternative ZnO source added at 220 mg/kg Zn could equally improve growth in the prestarter phase as pharmacological ZnO, whereas Raquipo et al. (2017) demonstrated that the alternative ZnO source at 220 mg/ kg Zn was advantageous over a coated ZnO source. The objective of the current study was to test the effects on gut microbiota and integrity in weaned piglets (prestarter phase) of conventional ZnO at nutritional and pharmacological dosage (110 and 2,400 mg/kg of Zn, respectively) compared to the alternative ZnO source at 110
and 220 mg/kg of Zn, dosages compliant to local legislation.
| MATERIAL S AND ME THODS

| Animals and diets
The study was conducted in accordance with the European recommendations for the protection of animals used for agricultural 
| Sampling
At d15, piglets were euthanized by electrical stunning followed by exsanguination. Subsequently, the entire gastrointestinal tract was removed. The small intestine (defined as the part of the gastrointestinal tract between the pyloric sphincter and the ileo-caecal valve; SI) was obtained, and its length was measured. A segment of 20 cm posterior to 75% of small intestinal length, referred as distal SI, was taken and rinsed with saline and used for Ussing chamber experiments. A mucosal sample at the same site was taken by placing another segment of 20 cm on an ice-cold surface after rinsing with saline. The tissue was slit along its length, and the mucosal side was softly cleaned with a paper towel to remove residual fluid. The mucosa was obtained by gently scraping with a glass slide. Mucosa was snap-frozen in liquid nitrogen and stored at −80°C. Next, the contents of the stomach and segments 0%-25% (proximal SI) and 75%-100% (distal SI) of small intestinal length were quantitatively collected, pH of the contents was determined, and aliquots were taken to determine Escherichia coli and coliform counts by plating technique and for qPCR quantification of bacterial groups. The remaining contents of stomach, proximal and distal SI were subjected to freeze-drying pending analysis for soluble and total Zn.
| Ex vivo measurements in Ussing chambers
Segments of distal SI were used to measure intestinal permeability and ion transport with the Ussing chamber system according to Wang et al. (2016) . In brief, for each piglet, the segment (20 cm) was flushed with saline, then cut along the mesenteric border, stripped of the muscle layers and mounted in modified Ussing chambers on a segment holder, as flat sheets with an exposed tissue area of 1.07 cm 2 .
Paracellular permeability of the tissue was assessed with the macromolecular probe FD-4, 4 kDa, in two chambers. Parameters of intestinal ion transport and the tissue integrity were assessed in two other chambers, including transepithelial electrical resistance (TEER), baseline short-circuit current (I sc ) and Cl − secretion stimulated by agonists:
serosal 0.1 mM 5-HT (serotonin, neural regulated secretagogue) and bilateral 5 mM theophylline (cAMP/cGMP-mediated secretagogue).
| Bacteriological determinations
Escherichia coli and coliform counts (viable counts; log 10 CFU/g fresh digesta) in digesta of stomach, proximal and distal SI were done using the ring-plate technique (Michiels, Missotten, Van Hoorick, et al., 2010) . Serial 10-fold dilutions were made from 1 g aliquots of fresh digesta, using a sterilized peptone solution (1 g peptone +0.4 g agar +8.5 g NaCl in 1 L distilled water) and plated onto selective media in duplicate. Selective media were used for counting the following bacterial groups: E. coli (Tryptone Bile X-glucuronide Agar, CM0945, Oxoid; incubated for 24 hr at 44°C aerobically) and coliform bacteria (Eosin Methylene Blue Agar, CM0069, Oxoid; incubated for 24 hr at 37°C aerobically). Denaturing gradient gel electrophoresis (DGGE) was applied to separate PCR products of the 16S rRNA genes of the overall microbial community composition. The general bacterial primers 338F-GC and 518R were used for PCR. Gels had a denaturating gradient ranging from 45% to 60% and were run using a DCode™ Universal Mutation Detection System (Bio-Rad, Nazareth, Belgium). Data analysis was carried out using GelCompar version 6.6 (Applied Maths, Sint-Martens-Latem, Belgium), enabling the calculation of richness and Shannon diversity indices. qPCR was applied for quantification of Lactobacilli,
Clostridium cluster XIVa (C. coccoides-E. rectale group) and
Enterobacteriaceae. The PCR mixture (total volume of 15 µl) con- Table S1 . Samples were checked for correct peaks in the melt curve. The standard curve in all of the different runs should have an efficiency between 95% and 105%. If not, the run was repeated. Each sample was analysed in triplicate, and outliers (more than 1 C T difference) in triplicates were omitted. Resulting values were converted to copies/µl by multiplying with 10 2 , that is, by taking into account the dilution (there was a 1:100 dilution of DNA extract prior to the qPCR).
| Soluble and total Zn in intestinal contents and mucosa
Soluble and total Zn in intestinal contents were determined as modified from Schlegel, Nys, and Jondreville (2010) . For total Zn measurement, freeze-dried contents were ground and ashed at 500°C
for 4 hr in a muffle furnace. Next, approximately 1 g of ashes was solubilized in 5 ml 16 N nitric acid and 5 ml Milli-Q, and digested for 2 hr. The digests were further diluted to 50 ml with Milli-Q and filtrated (45 μm). To determine the soluble Zn content, samples were rehydrated (approximately 0.3 g freeze-dried content and 10 ml
Milli-Q) and stirred constantly at 38°C during 2 hr. Supernatants were obtained by centrifugation for 1 h at 20°C and 18,000 g. Next, the supernatants were filtrated (45 μm). Mucosal samples of distal SI stored at −80°C were equilibrated to room temperature. Five mL of digestion acid (3:1:1; v/v/v; HNO 3 , HClO 4 , H 2 SO 4 , all concentrated) was added to approximately 1 g of wet tissue and heated to 110°C for 2 hr (Eller & Cassinelli, 1994) . The hotplate temperature was increased to 250°C until approximately 0.5 ml remained. After cooling, 5 ml Milli-Q was added. Finally, one drop of 16 N HNO 3 was added to samples (digests, supernatants and tissue extracts) prior to quantification by ICP-AES.
| Alkaline phosphatase activity in distal small intestinal mucosa
Alkaline phosphatase activity was determined using an alkaline A minus-RT control PCR was performed using primer for YWHAZ to verify the absence of gDNA. Subsequently, 1 μg of high-quality DNA-free RNA was reverse transcribed in the 20 μl reverse transcription reaction with the ImProm-II cDNA Synthesis Kit (Promega, Madison, WI, USA), containing both oligo-dT and random primers.
The obtained cDNA was diluted 10 times with molecular-grade water, and a control PCR using 2 μl cDNA was performed to verify the reverse transcription reaction. The RT-qPCR was performed 
| Statistical analysis
Data were analysed parametric using the mixed-model procedure in SAS Enterprise Guide 8.0 (SAS Inst. Inc., Cary, NC) with the fixed factor treatment and the random factor block according to a randomized block design with subsamples (two piglets per pen). Level of p < 0.05 is considered significant. The differences among treatments were determined by using the Tukey multiple comparison of means test. Data are presented as least square means with SEM.
| RE SULTS
| Animal performance and health
In general, performance was variable and very poor, though no serious health issues were noticed and diarrhoea incidence was limited. Observations showed that piglets failed to resume feed intake in the first two days of the experiment; hence, substantial body weight loss was found between d0 and 5 (Table 2) .
Faeces score and number of diarrhoea days were not significantly affected by treatment (Table 2) 
| Digesta characteristics and Zn contents
No significant effects on intestinal length and on pH, fresh matter content, dry matter and bacterial numbers in stomach and proximal SI were found (data not shown). However, regarding the proximal SI, a trend was observed whereby the treatment with 2,400 mg/kg Zn from conventional ZnO and with the alternative ZnO at 220 mg/kg Zn exhibited lower coliform numbers (p < 0.10) as compared to control. Further, with respect to distal SI, the treatment with 2,400 mg/ kg Zn from conventional ZnO was able to reduce the counts of E. coli and coliform bacteria versus control (p < 0.05) ( TA B L E 2 Effect of experimental diets fed to weaners (d0-15 post-weaning) on performance, faeces score and number of diarrhoea days (n = 4) treatment due to higher variation. Shannon index was highest in treatment with 110 mg/kg Zn from the alternative ZnO source (trend, p < 0.10); however, diversity was generally very low. Soluble and total Zn in intestinal contents reflected dietary dosages, but Zn solubility was not affected by treatment (Table 5) . Contents of soluble and total Zn in stomach and distal SI were highest in treatment with 2,400 mg/kg Zn from conventional ZnO (p < 0.05), but not different between the remaining treatments. Zn solubility varied between 34% and 43% in gastric contents, whereas it did not exceed 11% in distal SI contents.
| Distal small intestinal mucosal Zn content, barrier function and alkaline phosphatase activity
Surprisingly, the treatment with 110 mg/kg Zn from the alternative ZnO source showed higher Zn concentration in the distal SI mucosa (2,520 μg/g) than conventional ZnO at 110 mg/kg Zn (1,211 μg/g) and the alternative ZnO source at 220 mg/kg Zn (1,774 μg/g) (p < 0.05) (Figure 1 ), whereas value for treatment with pharmacological ZnO (1,947 μg/g) was only higher than conven- 
TA B L E 5
Effect of experimental diets fed to weaners (d0-15 post-weaning) on soluble and total Zn (mg/kg DM) and solubility of Zn (%; ratio soluble to total) in digesta of stomach and distal small intestine (SI) (75%-100% of length) at d15 (Table 6 ).
Transcript levels of TLR-4 and inflammatory cytokines were not affected. Finally, an increase in the mRNA levels of IAP in the distal SI was found for the both the alternative ZnO source levels as compared to 110 mg/kg Zn from conventional ZnO. A trend was found for alkaline phosphatase activity in distal SI, whereby the treatment with 2,400 mg/kg Zn from conventional ZnO showed the highest value (p = 0.084) (Figure 3 ).
| D ISCUSS I ON
The current study confirms the growth and gut health-promoting effects of pharmacological ZnO, corroborating with many previous reports and practice. Its use in weaner diets has been debated.
Therefore, new ZnO formulations applied at lower dosages, hence minimizing faecal excretion of Zn, that might provide equal efficacy deserves full attention (Michiels et al., 2017) . Interestingly, the alternative ZnO source tested in the current study exhibited positive effects on gut indices, albeit similar or better, depending on the dosage, to the effects of pharmacological dosage of conventional ZnO.
Interestingly, applied dosages of the alternative ZnO source were within the dose range of Zn allowed for nutritional purposes, depending on the area in the world. In this study, animal performances were very poor with substantial weight loss in the acute phase after weaning. It was noticed that feed intake was neglectable in the first 2 days after weaning, leading to malaise. Other factors that might have contributed to this lack of performance are the simple composition of the diet (Sulabo et al., 2010) , no growth-promoting Cu in the diet (Bikker, Jongbloed, & van Baal, 2016) and low weaning age (Gu, Li, & She, 2002) . With regard to the latter, weaning age was 20 days which is not uncommon in batch-farrowing farms with strict planning since it is observed that with modern hyperprolific sows gestation length increases giving an actual weaning age being lower than scheduled. In addition, the unfamiliarity of mingled piglets and low number of piglets per pen may have caused severe stress (Fels, Hoy, & Hartung, 2012) . Further, the basal diet contained a high level of supplemental Fe (500 mg/kg) to exacerbate gastrointestinal disturbances and burden the antioxidant system (Li et al., 2016) , though effects on feed intake are not anticipated (O'Donovan, Pickett, , & Beeson, 1963) . Li et al. (2016) showed that high Fe level (500 mg/kg DM supplemental Fe) reduced TEER and increased 3 Hmannitol fluxes in the duodenum as compared to 100 mg/kg DM supplemental Fe. As no low Fe treatments were included in the current study, the effects of high Fe level cannot be documented, though it is postulated that it contributed to poor performance in the current study. Earlier studies showed that high doses of inorganic Fe decreased Zn uptake as measured by changes in plasma Zn in human adults (Solomons & Jacob, 1981) ; however, the work of Lonnerdal (2000) in human subjects demonstrated that this might only occur when the iron-to-zinc ratio is very high (e.g., 25:1) and when given separate from meals, substantiated by work of Davidsson, Almgren, Sandstrom, and Hurrell (1995) . From this, it is unlikely that high Fe level in our diets interfered with Zn metabolism of piglets. Altogether, the current study posed a serious challenge for the piglets delaying gut maturation in response to the weaning event.
Plumlee
| Effects on microbiota of ZnO sources
Pharmacological ZnO was able to reduce numbers of E. coli and coliforms in the distal SI (by plating), without effects on Lactobacilli and
Clostridium XIVa (qPCR), underpinning its role in reducing diarrhoea (Starke et al., 2014) , and bacterial adaptation mechanisms to Zn, as shown by Starke, Zentek, and Vahjen (2013) . In our study, feed intake was low throughout the experimental period, which might be the reason why reductions in E. coli and coliforms were seen as late as two weeks after weaning. In addition, Fe is known to enhance E. coli growth, and indeed numbers of E. coli (7.0 log 10 cfu/g) and coliforms (7.2 log 10 cfu/g) in the distal small intestine of control piglets were substantially higher than in our previous studies (Michiels, Missotten, Van Hoorick, et al., 2010; Michiels et al., 2012) , leaving more room for reductions by experimental treatments. Most interestingly, we found clear proof that the alternative ZnO source showed similar effects on the gut microbiota as pharmacological ZnO, which is by far surprising as supplementary Zn levels for the alternative ZnO source were only 110 and 220 mg/kg. Vahjen et al. (2012) already showed that ex vivo, in chyme from donor piglets that was supplemented with ZnO sources, this ZnO source showed higher solubility and enhanced bacterial growth reduction more drastic and more rapid as compared to analytical ZnO at the same concentration. These authors suggested that the increased solubility may be responsible for these effects. However, assessing solubility in intestinal contents in our study did not show differences between treatments. Likely, specific physico-chemical features of the new ZnO preparation (Cardoso et al., 2017) TA B L E 6 Effect of experimental diets fed to weaners (d0-15 post-weaning) on mRNA expression of tight junction proteins, Toll-like receptor 4, inflammatory cytokines and intestinal alkaline phosphatase in the distal small intestine (75% of length of small intestine) at d15 (relative mRNA expression; n = 4) * F I G U R E 3 Box plot showing the effect of experimental diets fed to weaners (d0-15 post-weaning) on alkaline phosphatase activity (U/g mucosa) in the distal SI mucosa (at 75% of length of small intestine) (n = 4) (U is defined as the amount of enzyme causing the hydrolysis of one micromole of pNPP per minute at pH 9.6 and 25°C in glycine buffer)
higher bacterial diversity in the distal small intestine of pigs. The interpretation of this result remains unequivocal since it occurred only for 110 mg/kg Zn of the alternative ZnO source and not for the higher dose, and also diversity was generally very low so that relevance of this finding can be questioned.
| Zn contents in gut contents and mucosa
Both total and soluble Zn in intestinal contents increased with the dosage in the conventional ZnO groups, but this was also the case for the alternative ZnO source, suggesting that solubility was not affected by ZnO source and dosage. However, Vahjen et al. (2012) (Cario et al., 2000) . Nonetheless, others showed that pharmacological ZnO reduced mRNA of the ZIP4 and increased mRNA of ZnT1, but pharmacological ZnO did increase intracellular zinc, when compared to normal dietary Zn (Martin, Lodemann, et al., 2013) .
| Effects on mucosal function of ZnO sources
Intestinal TEER is a widely accepted parameter for the evaluation of the intestinal tight junction integrity (Srinivasan et al., 2015) . A higher value of TEER indicates a lower paracellular permeability (Lalles et al., 2004) . Our results showed that the alternative ZnO source can improve the tight junction integrity, while the pharmacological dosage of conventional ZnO only increased TEER numerically. Therefore, we speculate that the alternative ZnO source can improve the tight junction protein expression. Indeed, the mRNA level of CLDN-1 showed a trend to be higher in the alternative ZnO source groups, compared to the control group, indicating that the alternative ZnO source can improve the intestinal barrier function through enhancing CLDN-1 transcription. A recent study has outlined that two pathways exist during trans-tight junction transport. Claudins are essential to form a pore pathway for trans-tight junction transport, while ZO-1 and OCLN are important for the leaky pathway to allow small quantities of macromolecules to pass (Shen, Weber, Raleigh, Yu, & Turner, 2011 model that ZnO upregulated expression of heat-shock proteins, and they further suggested that this diminishes the induction of NF-κB response, and hence inflammatory response, upon exposure to ETEC, thus rendering a protective host effect, irrespective of any direct effect on the pathogen. Also, Song, Xiao, Ke, Jiao, and
Hu (2015) found enhanced intestinal barrier integrity by pharmacological ZnO through activation of ERK1/2 and inhibition of JNK and p38 signalling pathways. These authors deduced that inhibition of JNK and p39 signalling pathways might be secondary to downregulation of pro-inflammatory cytokine levels. However, in the current study, neither source nor dosage of ZnO affected the mRNA level of some pro-inflammatory cytokines. This is in line with the work of Hu et al. (2013) . Furthermore, the gene expression of the isoform IAP in distal SI mucosa was significantly upregulated by adding the alternative ZnO source. IAP has been highlighted for its multiple roles in maintenance of intestinal homeostasis, in particular for reducing inflammation by lowering the toxicity of LPS (Lalles, 2010 (Lalles, , 2014 , and it is well known that Zn is crucial to the catalytic function of the enzyme. However, when assessing alkaline phosphatase activity in distal SI mucosa, a trend was found suggesting that only in the piglets fed pharmacological ZnO a higher activity could be seen, in line with results of Martin, Pieper, Schunter, Vahjen, and Zentek (2013) . No explanation can be given for the discrepancy between IAP transcript and alkaline phosphatase activity. Cho et al. (2015) found with the same alternative ZnO source at 150 mg/ kg Zn higher alkaline phosphatase activity in plasma, corroborating with higher Zn levels in plasma. In that study, these effects of the alternative ZnO source were equal to pharmacological ZnO.
However, plasma alkaline phosphatase activity should not necessarily correlate with similar enzyme activity in the GIT or potential beneficial effects, in particular because different isoforms exist in small intestine (IAP isoform) and colon (IAP and TNAP isoforms) whereby expression has different interpretations (Lalles, 2014) . IAP in small intestine is perceived as an anti-inflammatory and protective response, whereas TNAP is associated with neutrophil infiltration. Possibly, the higher IAP mRNA levels with the alternative ZnO source in our study might be related to the higher Zn concentration in the mucosa, though this warrants further attention.
| CON CLUS IONS
Pharmacological ZnO is well known to prevent scouring in weaned piglets. However, this common practice poses high risk for contamination of the environment and development of bacterial antibiotic resistance. Therefore, new ZnO formulations applied at lower dosages that might provide equal efficacy deserves full attention.
Here, we showed that an alternative ZnO source at 110 and 220 mg/ kg Zn showed positive effects on gut microbiota and function albeit similar or better, depending on the dosage, to the effects of pharmacological dosage (2,400 mg/kg Zn) of conventional ZnO, thus offering pig producers potential alternatives to reduce post-weaning gut disorders.
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